C-IG6JAugustine Therapeutics
HDAC6 inhibition, non-hydroxamate chemotype
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-IG6J
C-IG6JC-IG6JHDAC6 inhibition, non-hydroxamate chemotype
0-100 chain-logic scale · 15 dimensions · scored on public evidence
In 2023, CMTRF invested $683,000 in Augustine Therapeutics to support their groundbreaking work on a small-molecule HDAC6 inhibitor for CMT. That investment became the foundation for something extraordinary — Augustine leveraged those initial funds to advance and optimize their lead drug candidate, AGT-100216, and attract additional funding of $85 million. This funding will be used to advance their CMT drug candidate through clinical trials, marking a major milestone in CMT research. In this exclusive webinar, Augustine Therapeutics’ CEO, Gerhard Koenig, Ph.D., and advisor, Dr. Andy Hu, along with the team from CMTRF, discussed how this remarkable fundraising success happened, the science behind their promising HDAC6 inhibitor, and what this breakthrough means for the future of CMT treatments. To learn more, visit https://cmtrf.org/
Moderator: Arthur Suckow, PhD, Board Member, CMTRF Panelists: David Goldstein, PhD, Co-Founder and CEO, Actio Biosciences Ilan Ganot, MBA, CEO, Alesta Therapeutics Tim Piser, PhD, Head of R&D, Samsara Rachel Salzman, DVM, CEO, Armatus Bio Gerhard Koenig, PhD, Executive Chairman, Augustine Therapeutics To view the full agenda and convention details, visit https://cmtconvention.cmtrf.org/2024-global-cmt-research-convention/
Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
VIB.BE - Annual Report 2019 Skip to main content VIB.BE Search Search en English Dutch About Research & Impact Research Areas Immunity & Inflammation Cancer Research Medical Biotechnology Neuroscience Plant Biology Microbiology Structural Biology Computational Biology Research Centers Center for Cancer Biology VIB.AI: Center for AI & Computational Biology Center for Inflammation Research Center for Medical Biotechnology Center for Microbiology Center for Molecular Neurology Center for Structural Biology Center for Plant Systems Biology VIB-KU Leuven Center for Neuroscience Grand Ch … act IPBO Biotech for security and public health resilience Aureus Nova Scientia Prize Publications Responsible Research Why animal research is necessary Research Infrastructure ESFRI Business Business Development VIB’s Business Development team Technology transfer New Ventures From idea to spin-off Embarking on a long-term adventure VIB's Spin-offs Intellectual Property Ecosystem Biotope Discovery Sciences Internship program AI Studio Success Stories Towards a COVID-19 D … act IPBO Biotech for security and public health resilience Aureus Nova Scientia Prize Publications Responsible Research Why animal research is necessary Research Infrastructure ESFRI Business Business Development VIB’s Business Development team Technology transfer New Ventures From idea to spin-off Embarking on a long-term adventure VIB's Spin-offs Intellectual Property Ecosystem Biotope Discovery Sciences Internship program AI Studio Success Stories Towards a COVID-19 D … rst name* Last name* Email* Organization or company Please verify your request* Submit Contact Donate Sitemap VIB Suzanne Tassierstraat 1 9052 Ghent Belgium BE 0456 343 923 +32 9 244 66 11 [email protected] Follow us facebook instagram bluesky youtube linkedin vimeo © VIB Cookie policy Disclaimer Privacy Administrator login
Augustine Therapeutics | PMV For whom? Offering Jobs en nl Menu Search 02 229 52 30 For whom? Offering Expertise Portfolio PMV About us Contact Jobs Back Real estate Clean tech & Industrials Life Sciences & Care Acquisitions Energy Start Growth Back Mission and vision Team and organisation Publications Corporate governance Legal structure Newsletter Cases Augustine Therapeutics Start-ups & scale-ups Life Sciences & Care Portfolio Life Sciences & Care Life sciences & care Start PMV is one of the investors in Augustine Therapeutics, a new venture of the Flemish Institut
%PDF-1.4 %���� 4 0 obj > stream ����JFIF���ICC_PROFILE�0mntrRGB XYZ �acsp���- desc�$rXYZgXYZ(bXYZ ��I�����O���t�쯞�����9D�9 � �|v���$-���3�+`+ \�} �����mS b!̻��FI�ձ���"����`1��7(�3��L3��|� I���K#���'c����7�~�f`����#���� �>������`#�`� 0� =s����ձom�XY�6nW����=3��~�砩�J(b:OC�o��k�+� r9�������L�0z|�e5 S�C�p!�)��!����;㮨x����av���^��z���T�F`��=~�6����J�L�(��t���a0��0 ���]T@�H��4 � #c����n� ���vA �"�9!�r >�� ���$7�+r�H\g��0rFz�8냀v�CD��g�����=7튎e��� q�z�u���=�>z��t6�*���A;��v���R�L8� ��o��|�W����z� !�=l���@q���>zk�>�u̞j�;,v� … [x&W�{c�K$d�#42f,�B+J2�[�-��Qk^[��_����+�5 w��m�?M#o`jw�����^�^���5~��,��(ӄrfP�)����m�[��n�f�toʩu,��HT�yZ� fe �ܬ}9�5��|�kRu j�� ���8��r��Y��P����f�oʄ՟[�� s���ݭ�W���T֚�4Ju bK3eQC�j�j��c�UEd��?!.F�]e��rvJ.�͎�����[q�e�[)Hoa�19 �8f�h\��WNl�s�i-sI��uk�*�Kg7 �AQ,d !�A$��6G$� �}�Ư&���Xӱ���l��v˖g�u�*>��L��"�ˢ��wu�[�j�]�}���%��q=���YZWx�D$y�c�!r���oσ֖�T�:f�y5��Nb�H ^Rh�X�$���ZK�[ @�m5�%������!~h�7QS���S3�;U�C�BI"ڥ�y�xѵ Z�D��q!� &����b��l�]���j��īd�kYj … ��� ���K�PK���:�O3O��F�RB��rp0G��� �����?�W�)&���vߘ:+ lA ��z�V9����؍v� �|rFp}�D���'|m��~O��3H�{�~�W�g�����;c�y�#%90��߶1���q���������r8��b���9P?� �x[��� �7\���̵����X]A�C��1��v��k ��&%��R;t���ϥ��J������� ߠ�w��?>͵�������[p$c�{��9��I � dd�c9�݃��Z�s�Z{�#���U o� �����p4w��M�8�r�Ie!��n? �[O ��D���F��Xa�� ��_}�5v�~Ѻ�Sr59;$�NT{k��'}�j�ǂ�:G���@��p-��l�v4u�NԖM��i�.pI�����iNw8���(__�� w �7@~o믹?�h�vt 8��.�u��mA,�q��c��3���pw�dH���!J�eg[���d0� �Si�\I
Charcot-Marie-Tooth Disease Market Growth to Accelerate Significantly During the Forecast Period (2026-2036) Driven by the Launch of Emerging Disease-Modifying Therapies | DelveInsight Accessibility Statement Skip Navigation Resources Investor Relations Journalists +44 (0)20 7454 5110 Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All Public Com … ed the requirements to support a potential future NDA, and the company plans to submit another meeting request to further discuss the design of a potential Phase III trial for the development of govorestat in CMT-SORD. In September 2025, CMT Research Foundation announced that it had funded Elpida Therapeutics to launch manufacturing of a gene therapy drug for CMT4J. The announcement came at the 2025 Global CMT Research Convention. In June 2025, Vanda Pharmaceuticals announced … ces Blog Journalists Data Privacy Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Customer Portal Resources Blog Journalists +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookie Settings Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company. --> --
CMTRF News and Updates | CMT Research Foundation CMTRF News and Updates | CMT Research Foundation What is CMT? About CMT Type1 What is CMT1A? What is CMT1B? What is CMT1E? What is HNPP? Type2 What is CMT2A? Type4 What is SORD? TypeX Understanding CMT1X/CMTX1 and GJB1 —- Watch Our Video Series Learn About Treatments in Development Research Research Approach Research Projects We Fund Research Pipeline Gene Therapy Clinical Trials —- Apply for Funding Emerging Researcher Award News & Stories News CMT Stories Take Action About Us Who We Are Board of Directors Research Advisory Cou … MT Research Convention that it has surpassed its goal of raising $10 million to fund research... read more Actio Biosciences Receives Both Orphan Drug and Rare Pediatric Disease Designations From the FDA For Treatment of CMT2C Aug 9, 2024 | CMT Research Updates , Research News Actio Biosciences recently announced that they have received both orphan drug designation and rare pediatric disease designation for ABS-0871, a TRPV4 inhibitor, for the treatment of TRPV4+ Charcot-Mari
Investor Profile We're sorry but this website doesn't work properly without JavaScript enabled. Please enable it to continue.
Augustine Therapeutics - Executive Bio, Top Executies, and Transitions - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Organization Augustine Therapeutics augustinetx.com Company Details Description Augustine Therapeutics is a Belgian biotech company, founded in 2019 and a spin-off company of VIB-KU Leuven. The company is building a portfolio of best-in-class small m … nounced in January 2025. He is an advisor with Atlas Venture, a Boston-based VC fund, and is Board member on VIGIL Therapeutics. Prior to his current positions, Gerhard served as CEO of Quartet Medicine, CSO and Senior Vice President of FORUM Pharmaceuticals, Vice President of Scientific Programs and Evaluation at Fidelity Biosciences Group (now F' Prime Capital), and held multiple positions at pharmaceutical company Bayer. Gerhard received his PhD and MS degrees in molecular … ard member of the Peptide Therapeutics Foundation and a member of the DCAcademy Grant Committee (University of Copenhagen) and obtained her post doctorate in cardiovascular research. Read More Andy Hu Chief Business Officer Andy brings diverse experience in corporate finance, strategy, and business development across the life sciences industry. Before joining Augustine, Dr. Hu was Chief Business Officer of Arkuda Therapeutics, a biotech company focused on neurodegenerative di … nounced in January 2025. He is an advisor with Atlas Venture, a Boston-based VC fund, and is Board member on VIGIL Therapeutics. Prior to his current positions, Gerhard served as CEO of Quartet Medicine, CSO and Senior Vice President of FORUM Pharmaceuticals, Vice President of Scientific Programs and Evaluation at Fidelity Biosciences Group (now F' Prime Capital), and held multiple positions at pharmaceutical company Bayer. Gerhard received his PhD and MS degrees in molecular … ard member of the Peptide Therapeutics Foundation and a member of the DCAcademy Grant Committee (University of Copenhagen) and obtained her post doctorate in cardiovascular research. Read More Andy Hu Chief Business Officer Andy brings diverse experience in corporate finance, strategy, and business development across the life sciences industry. B
Augustine Therapeutics | Valuation, Funding Rounds & Stock Price | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Companies Augustine Therapeutics Augustine Therapeutics Private Leuven Healthcare & Life Sciences https://www.augustinetx.com/ Last Round Series A Mar 24, 2025 Total Funding Raised $108.08M Momentum Score 50 /100 Company Overview Augustine Therapeutics is a biotechnology company that develops therapeutic drugs designed to treat neuromuscular and neurodegenerative diseases. Sector Healthcare &a
Charcot-Marie-Tooth Disease - Research and Clinical Trials L CMT WHAT IS CMT Charcot-Marie-Tooth disease (CMT) is one of the most common inherited nerve disorders. TYPES OF CMT Description of the most prevalent types of CMT. PATIENT RESOURCES Helpful patient care resources for the treatment & management of CMT. CMT UPDATES Read about CMT updates and the latest in CMT research. Access our archives since 2014. CMT CONNECT Webinars. Empower, Educate, Connect. CMT Research = TRIAD Therapeutic Research In Accelerated Discovery TRIAD = Academia + Government + Industry = GRIN PATIENT REGI … ss release announcement about ignaseclant (previously... Allison Moore Receives Award for Community Impact in Research by Courtney | Jan 14, 2026 | Advocacy , Awareness , Featured , Gene Therapy , GRIN Patient Registry , Living with CMT , Research , Research and Critical Trials , TRIAD | 0 Comments Muscular Dystrophy Association’s Legacy Awards Honor Innovators in Clinical and Scientific Research, and Community Impact at the 2026 MDA Clinical & Scientific Conference in Ma … Impact at the 2026 MDA Clinical & Scientific Conference in March MDA Legacy Award for Achievement in Clinical Research to honor Michio Hirano, MD,... The Nerve to Cure Event, Columbia Missouri by Courtney | Aug 26, 2025 | GRIN Patient Registry , Living with CMT , Patient-Focused Research , Registry , Research and Critical Trials | 0 Comments Join us Saturday, October 4th from 12pm – 8pm October 4, 2025 The Nerve to Cure CMT Social + Science Day with Evening Fundrais
%PDF-1.4 %���� 4 0 obj > stream 0��@&��������������Z�SO�� !��Dk�j&�`��)��C4}�# G� �{�� �V #�_ ��eFa"���'�A ��i��/��X�҅ײC�w� py>�0��!B�y�F+ A�7��xZnCيg� �_d��+�ߞ'��s��� b�'��Z�`ߌ����X溃����4�,���ld�;���/��8)��4ב�-�14`�x(�!�FjR�|���qp�`"�ꨀ;��鑖W����B3_PZ�x�w�Z��~13�Y� ���f?�S�*���V���HM��� �P���ԢX�d G�ڔl]�с�e2xb��ay; ����ؑ`ڟJY�K+���ޞ��d�;懓��J��Q��8�֘�\!�%�x�ZA�]�J̿ӭ� ����;��*�깋� ����N�t�P,�X{��r�l��* ,�.5Z���L��jb�Cӟax��!J .�����% �:2G2�$�1W�@Hzli��� ;� ��)�h-�ܼ� j�$�f�iI ���k)D��k L��̚#����J=�/V�[6�Rm� �A��y��e����m���ǐ"�#E�龻sH6t4-�{�Q��h� �W�S … U3���Ҷ{�`�� !��B��k��;\�7ԶQ����u�����u�edP�Ǟ ��J|��[��V�o�������Y��f�/�i��rFP���w �Py���}W����I���hKK$� �έAǿ�ԍ5� �.�R��^ � ǜr��F[k�n;q ����/7��c�����{x���g���\���}�2��r��?��#�e���1� hkN�q�J{�����S����wds����S�W{��m���P�k�[�5�r�R����V�u�ָ�Bݺm����+������Ƿ_�t+�gG��R�i{Z !���� )��ۧ�>�㟚���2� ��I���.��'�쟫ns c]Q�����O�+E�ʙ�F�]?2��j ���o�y�� �d| K���òn�KF�2�'�6F]n� `�������\?��o��n��e'��8�����NIE�y� I)��u�>��=Ƽf����~��U� #�SMt1�t�#yo���C�S�^G��~�;�
#appointment #augustinetherapeutics #hdacs #augustinetx #neuromusculardiseases #neurodegenerativediseases #cardiometabolicdiseases #cmt #cmta #charcotmarietooth | Augustine Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . A … d #inflammatory diseases. 🚀 The FDA cleared our Investigational New Drug (IND) application for TRX319. Our off-the-shelf CAR-Tr1 will now enter a Phase 1/2a clinical trial for progressive Multiple Sclerosis in early 2026. 📈 We also announced a $50 million financing that extends our cash runway well into 2027, allowing us to initiate the TRX319 study and execute on our ongoing Phase 1/2a trial of TRX103 for patients with refractory #Crohn ’s disease. Learn more: https://lnkd … d #inflammatory diseases. 🚀 The FDA cleared our Investigational New Drug (IND) application for TRX319. Our off-the-shelf CAR-Tr1 will now enter a Phase 1/2a clinical trial for progressive Multiple Sclerosis in early 2026. 📈 We also announced a $50 million financing that extends our cash runway well into 2027, allowing us to initiate the TRX319 study and execute on our ongoing Phase 1/2a trial of TRX103 for patients with refractory #Crohn ’s disease. Learn more: https://lnkd
Augustine Therapeutics Raises $18.5 Million in a Series A First Closing | CMT Research Foundation Augustine Therapeutics Raises $18.5 Million in a Series A First Closing | CMT Research Foundation What is CMT? About CMT Type1 What is CMT1A? What is CMT1B? What is CMT1E? What is HNPP? Type2 What is CMT2A? Type4 What is SORD? TypeX Understanding CMT1X/CMTX1 and GJB1 —- Watch Our Video Series Learn About Treatments in Development Research Research Approach Research Projects We Fund Research Pipeline Gene Therapy Clinical Trials —- Apply for Funding Emerging Researcher Award News & … V-Bio Ventures, PMV, VIB New Ventures and KU Leuven’s venture arm Gemma Frisius Fund. The proceeds from the Series A will be used to advance Augustine’s first clinical candidate AGT100216 into a Phase 1/2 clinical trial in 2025. Next-generation drug candidates with additional peripheral-restricted and brain penetrant properties will follow thereafter, moving towards non-clinical regulatory development stage. A year ago CMTRF also helped Augustine Therapeutics underwrite the d
%PDF-1.6 %���� 1 0 obj > endobj 2 0 obj >stream 2025-03-31T01:46:28-04:00 2025-03-31T01:46:28-04:00 2025-03-31T01:46:28-04:00 Acrobat PDFMaker 24 for Word uuid:c53437f6-bc61-11b2-0a00-000000000000 uuid:c534522c-bc61-11b2-0a00-9b0100000000 application/pdf VIGL- 2024 ARS.pdf Pam Meneses Acrobat Distiller 10.1.16 (Windows) endstream endobj 3 0 obj > endobj 5 0 obj > endobj 6 0 obj > endobj 7 0 obj > endobj 8 0 obj > endobj 9 0 obj > endobj 33 0 obj > endobj 34 0 obj > endobj 35 0 obj > endobj 36 0 obj > endobj 37 0 obj > endobj 58 0 obj >/BleedBox[0 0 612 792]/Contents 63 0 R/CropBox[0 0 612 792]
Augustine Therapeutics builds its Management Team with --> Accessibility: Skip TopNav Augustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO April 30, 2025 07:00 ET | Source: Augustine Therapeutics Augustine Therapeutics Augustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO New recruits expand senior team capabilities as the business progresses its lead HDAC6 inhibitor program, AGT-100216, into the clinic for the treatment of Charcot-Marie-Tooth disease LEUVEN, Belgium – 30 Apr … Eli Lilly and Company, AdBio partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, the US-based Charcot-Marie-Tooth (CMT) Research Foundation and Newton Biocapital. For more information visit www.augustinetx.com Tags Appointment HDAC6 Board New Hire GlobeNewswire Recommended Reading June 02, 2026 07:00 ET | Source: Augustine Therapeutics Augustine Therapeutics to Present Late-Breaking Poster at the American Diabetes Association’s 86th Scientific Sessions Poster will featur
#als #innovation #hdac6 #therapeutics | Augustine Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privac
Augustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological Diseases | VIGL Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S- … n. Current investors AdBio partners, V-Bio Ventures, PMV, VIB and Gemma Frisius Fund also joined the round. Augustine Therapeutics is developing best-in-class, novel, potent and subtype-selective small-molecule inhibitors of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, a class II histone deacetylase. HDAC6 is a well-known molecular target with strong biological rationale for neurological disorders and high therapeutic potential in cardiometabolic disease. Inhibition of … trant properties for cardiometabolic and neurodegenerative diseases, as well as fund the expansion of the Augustine executive and R&D team. “The support from both new and existing investors in this first closing is a reflection of the tremendous efforts and scientific excellence of our team in advancing a unique pipeline of potential breakthrough therapeutics for patients,” said Sylvain Celanire, CEO of Augustine Therapeutics. “Our HDAC6 inhibitors have unique properties
Donations — East Texas Chamber Winds East Texas Chamber Winds Home About Contact Events Donations News Photos Concert Program Back Our History Musicians Archive Board of Directors Home About Our History Musicians Archive Board of Directors Contact Events Donations News Photos Concert Program East Texas Chamber Winds Music for the sake of music. Donation FAQ The East Texas Chamber Winds is a 501 c 3 non-profit arts service organization. Contributions for the charitable purposes of East Texas Chamber Winds are tax deductible to the extent permitted by law. Who should I contact with
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
%PDF-1.7 2 0 obj [/PDF /Text /ImageB /ImageC /ImageI] endobj 10 0 obj > stream X ��[o�6���w Зvёś.�'Υ�\{�-��B3V&ڱ��t����{$�дe��p���?�?��t(���oQʉH� M8�Y�P�r� )�Me�Z�62 ���pi��s2��� MS2"a�O��DpU��S�CPΉd,��lA�W$ 8\��*�xE�c!�ߓ����d2�/畫�ARr�~�l�%���?�?�����q[i�2�c�ZmJ��/e���[�T�w ���p)���#�> 4wD�NH�� �MH�u���D˦%�{8��Bwƍgc�����1D���h��� ��J�0I(� /��?���X��l���T�6�ݜ��&_P��`Q������ޱ�9��9{�,��Yֶ)����#4�NM�� � գ�t�(���z�*O5IO��/�6�� 矻w|=Y�ZM�ӭ�+�r�z��/߽�Y,�9�|���r�|�D��2Qr`�������E��0�W��d4�� �*v���S��Vٕ���tx{�*�(WJ�u�z`b�x��J�B)Ҿ+�}�5��������x��#����j�
Error Facebook Facebook is not available on this browser To continue using Facebook, get one of the browsers below. Learn more English (US) + Meta © 2026
%PDF-1.4 %�쏢 5 0 obj > stream x��}[� �qf�qe� E ��ߝ���a^ϯN{G�x�ίM-M8�>E�ޚ���²Z����� f��p~k"llL���ioi5�֦~�e|�����L����y��l.r�gҍe��y��oO{s0� {X����I�R&��Zޚ q�8x�~�o�pR���ˤXR�@���M,5�&����w7�- �|v�$��0�T.�|A2�.�Ĉ��E��tw$:�K���A��i�m��!���L ����!z��rMr� ��}��\�6 !�.3��$\s��ݡ��po�kVHj*W4nm���ow�-FTC�BPCdD��@�8cwW�� $A��f���B$���E�� L M��y�-Z��gA�N�p����ܐYp��4�}�|���T=��� �_H�2� ��).L궷)�poZyj�j������_J� _�&��D�F����O��1_�=�����DZ��x(�lhs&Ԁ�J��� S��iN� g�g� ϯ�����y �6W� ���l��H\Q�#�f���I�K� �g�n�!4f֤���N���'k�b�.島�ƻ�0/;g)VS�}DyY�ԩ�*B+5�P�>�L
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Home - Asabys Partners Skip to main content Search Close Search Menu HOME PORTFOLIO TEAM NEWS CONTACT FOR INVESTORS Fostering breakthrough innovation in healthcare Asabys is an investment firm based in Barcelona , investing in healthcare and life-sciences innovation. PORTFOLIO TEAM Impact We want to push the boundaries of science and medicine improving patient’s life Disruptive We look for highly innovative and transformative technologies Hands-on We consider ourselves partners and collaborators to our portfolio companies Our portfolio Accure Therapeutics Accure Therapeutic
Biotech Fundraising Highlights – Jan to Jun 2025 | Khan Ozol, PhD LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Pri … estors include 4BIO Capital , Cancer Research Horizons , Brain Tumor Investment Fund , Meltwind Advisory LLP , LongeVC , Calculus 🦠 Ovid Therapeutics (NASDAQ: OVID) raised $81M via PIPE (plus up to $94M from warrants) after positive Phase 1 data for OV329 (GABA-AT inhibitor) 🦀 Cartography Biosciences raised $67M Series B with Pfizer Ventures and Amgen Ventures to start a Phase 1 for CBI-1214 (LY6G6D TCE) in colorectal cancer. New and existing backers include LG Electronics … ibitor), already approved in parts of Asia New Funds 🏦 Ascenta Capital — $325M Fund I (Lorence Kim & Evan Rachlin): Focus on leading/co-leading early human trials stage companies (board seats), already in ADARx, Iambic, Odyssey, Cardurion, Alpha-9 Oncology, OrsoBio 🏦 TCGX — $1.3B Fund (later-stage/catalyst-driven): Public-markets specialist targeting drug-centric stories with near-term readouts; recycling exits to redeploy capital; ~$30–$75M sweet spot per deal As alway … rian cancer Peptilogics $𝟕𝟖𝐦 𝐒𝐞𝐫𝐢𝐞𝐬 𝐁𝟐 (Oct 16): Thiel Bio, Founders Fund EXCELERGY $𝟕𝟎𝐦 𝐒𝐞𝐫𝐢𝐞𝐬 𝐀 (Oct 13): Samsara BioCapital Cartography Biosciences $𝟔𝟕𝐦 𝐒𝐞𝐫𝐢𝐞𝐬 𝐁 (Oct 2): Pfizer Ventures, Amgen Ventures Tr1X $𝟓𝟎𝐦 (Oct 14): Cell therapy for Crohn's OncoC4, Inc. $𝟓𝟎𝐦 𝐒𝐞𝐫𝐢𝐞𝐬 𝐁 (Oct 2): PD-1/VEGF blocker Phase 2 Key trends: Obesity megarounds continuing, ADC wave intensifying, Flagship/Moderna vets launching with Big Pharma deals pre … brutinib (Phase 3 MS) and two early-stage programs, alongside a $120 M raise to fund development. Overall, deal flow rebounded sharply led by metabolic and immunology assets, creative financing structures, and continued East-West licensing momentum. View C2PA information 16 2 Comments Like Comment Share Copy LinkedIn Facebook X To view or add a c
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
CMT Research Foundation | Portfolio, Investments & AUM | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Investors CMT Research Foundation CMT Research Foundation Atlanta, Georgia cmtrf.org Overview A patient-led, 501(c)(3) non-profit organization focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease. The foundation funds and invests in scientific research and drug development, identifying and supporting promising projects with a high potential of leading to clinical trials and appro
EU-Startups - TRIMTECH Therapeutics Limited, a... Facebook EU-Startups's Post EU-Startups 3d · Shared with Public TRIMTECH Therapeutics Limited, a Cambridge-based BioTech company developing new treatments for neurodegenerative diseases, has raised an additional €12 million in Seed funding The financing was led by Johnson & Johnson’s corporate venture capital organisation, Johnson & Johnson Innovation – JJDC, Inc., and BGF, who join existing investors. This brings the total for the round to €41 million – following a previous raise. Dr. Nicki Thompson, CEO, TRIMTECH Therapeutics, sa
Mission Dolores | Texas Historical Commission Skip to main content Menu Preserve Preserve Home Archeology in Texas Archeology in Texas Overview Texas Archeology Month Curatorial Facility Certification Marine Archeology Regional Archeology Historic Texas Lands Plaque Texas Archeological Stewardship Network Publications and Resources Public Outreach Materials Archeology FAQ Preservation Programs Preservation Programs Overview Historical Markers Courthouse Preservation County Historical Commission Outreach Museum Services Cemetery Preservation Disaster Assistance State Historic Site Preservation … and Funding Overview Historic Preservation Tax Credits Texas Preservation Trust Fund Certified Local Government Grants Courthouse Grant Program Museum Grants and Fundraising Additional Funding Sources for Preservation Projects Tourism and Economic Development Tourism and Economic Development Overview Texas Main Street First Street Initiative Museum on Main Street Heritage Tourism Texas Treasure Business Awards Texas Heritage Trails DowntownTX Preservation Awards Travel Travel
Novo Holdings · Investments About Novo Group Leadership Responsibility Novo Nordisk Foundation About Investments Areas Life Science Seed Investments Venture Investments Principal Investments Planetary Health Investments Capital Investments Strategy Regions North America Europe Asia Portfolio Investments People Careers Open positions People & Careers News & Reports Facts & Figures Media Library Contact Public Relations News & Reports Investments Scroll to learn more Currency DKK 694 bn Total Assets under Management 8.6% 10-year average annual return on the investment portfolio 1 … build long-term relationships with specialist external equity and fixed income fund managers; make direct public equity and bond investments in high quality companies with a long-term sustainable growth profile and capital allocation discipline; make credit investments in companies that appeal to our risk/return requirements; make both direct and externally managed Real Asset investments in infrastructure, green transition and real estate assets; and invest in specialist ven … stment Regions North America Europe asia Our Investment Portfolio Filter Search Apply filters Clear all filters Sort by: Newest Oldest Alphabetical (A - Z) Alphabetical (Z - A) Responsible Investments at Novo Holdings We recognise that the health of people and the health of our planet are intricately intertwined, and we are determined to play our part in securing a more sustainable future. Our Responsible Investment report offers a comprehensive review of our investments and
%PDF-1.6 %���� 330 0 obj > endobj 376 0 obj >/Filter/FlateDecode/ID[ ]/Index[330 58]/Info 329 0 R/Length 197/Prev 5102184/Root 331 0 R/Size 388/Type/XRef/W[1 3 1]>>stream h�bbd```b``^ "CA$C�db���H� `�$X|+X�)� �{L�ř~�����`� �� "�~�H ��0�~�b�� +@�TH�b,�=����"�D4���R ��8X'�t���?6�/� �"e�A��m��xYv��5��2�y � �/��o���� L� �7�>e`$����(� ���#� endstream endobj startxref 0 %%EOF 387 0 obj >stream h�b``g``�����" � ̀� , l@̱&���c���汓��{�W][s�)S��������q�!�DA����4�@`;ہ#"I� 2� H�� \�B{yG3�W@)��n�q��@�낅L�3JW3 > endobj 332 0 obj > endobj 333 0 obj >stream h�|�A … h�262S0P062W02P����+�-��(���ł�]�� �| _ endstream endobj 281 0 obj >stream application/pdf ktolbert03 HHS001705700009-contract.pdf 2026-04-08T14:54:36-05:00 PScript5.dll Version 5.2.2 2026-04-08T14:55:00-05:00 2026-04-08T14:55:00-05:00 Acrobat Distiller 23.0 (Windows) uuid:ca034daf-10a8-4001-80e0-ff604e82a36f uuid:97fb3628-549a-41b4-abef-4cb9871d313a endstream endobj 282 0 obj >stream h�26�P0P���w�/�+Q����L)�666�)�Ien34�Ц������B����X��ʂT�����b;;���d endstream
2026 Participating Companies - BIO Partnering™ @ JPM Week 2026 Skip To Main Content Home Partnering Show submenu for: Partnering BIO Partnering™ Participating Companies Participating Investors BIO Partnering Mobile App LOG IN TO BIO PARTNERING Webinars Show submenu for: Webinars Investor & Exec Panel Partnering Tips and Tricks Plan Show submenu for: Plan Social Media Toolkit BIO Partnering Mobile App JPM Events Guide App FAQs Sponsor More Show more menu items January 12-15 | San Francisco Marriott Marquis January 12-16 | Virtual Home Partnering Show submenu for: Partnering BIO Partnering™ … 20n Bio 28 Capital 28bio 2Flo Ventures 3D BioFibR Inc. 3Helix 3i Corporation 3i Fund 3i Partners 3S Bio Pharmaceutical Group 5Y Capital 6 Dimensions Capital 7 Hills Pharma, Inc. 7G BioVentures 88Helix Ventures A&J Science Co., Ltd. AAA Family Office Aavnergene Inc. AB Family Office AB Science AbbVie Contract Manufacturing Ability Biotherapeutics Ability Pharmaceuticals ABION Inc. Able Tx Ablexis, LLC Absci Absco Therapeutics AbTherx AbVir Biotherapeutics ACADIA Pharmaceutical … Therapeutics, Inc. AcuraStem Inc. Acurex Biosciences Corporation ADA Innovation Fund Adelphi Ventures_Jae Won Kim Adial Pharmaceuticals Adimab, LLC Adipo Therapeutics, LLC AdipoSeeds Inc. Adiso Therapeutics Aditum Bio Adjuvant Capital ADM Healthcare AdvanCell Pty Ltd Advantary Capital Partners Adze Biotechnology Inc Aegis Capital Corp. Affinity Biopharmaceutical Co., Ltd. age1 Agilex Biolabs AIAC Group (SFO)_Robert Colorina AIcloud Ailux Aimed Bio, Inc. Ainnocence AION Labs A … ma Limited Anaveon AG Anaxis Pharma Angel Investor Forum Angelonia AI AngelVest Fund AnGes, Inc. Animuscure Inc. anlongbio Anne K. Vallerga Family LLC Anodyne Antabio SAS ANTELOPE THERAPEUTICS Apellis Pharmaceuticals, Inc APEPTICO Apertor Pharmaceuticals Aperture Therapeutics Aphios Corporation Apollo Health Ventures Applied Cells Inc. Aprea Aprecia Pharmaceuticals Company AprilBio Co.,Ltd Apriori Bio, Inc. Aptarion Biotech Aquestive Therapeutics Aquillius Ventures Archer The … ies Baerenkraft Therapeutics Baheal Pharma Group Bantam Pharmaceuticals Baoying Fund Management Barings Base4 Biotechnology Basestones Capital Bassler Lab at Princeton Bayer Bayland Capital BeBetter Med Beiersdorf Corporate Venture Beijing Inno Medicine Co., Ltd. Better Biostatistics Bexion Pharmaceuticals Beyond Next Ventures BeyondBio Inc BEYON
Augustine Therapeutics. Biotech | Current Portfolio of Jeito Capital (2025) | GP Intel Skip to content GP Intel . Search a GP, fund, or company ⌘K GPs Companies Pricing MCP About Sign in Start free Home / Companies / Biotech / Augustine Therapeutics AT Augustine Therapeutics Biotech · Belgium · Active · 1yr hold Augustine Therapeutics is a healthcare company, headquartered in France. Entry 2025 Hold 1yr Status Active Est. EV – Who owns Augustine Therapeutics ? Augustine Therapeutics is currently owned by Jeito Capital through Jeito II (2026 vintage), since 2025. Across its history, Augustine T … -invest · 2 holders · 2019 · present AdBio Partners Active 2019 · present · AFB Fund I · 2021 · VC MOIC – Jeito Capital Active 2025 · present · Jeito II · 2026 · VC MOIC – More from Jeito II Other portfolio companies in the same fund. Adcendo Active Biotech Denmark · 2026 Alveus Therapeutics Active Biotech US · 2026 Azafaros Active Biotech Netherlands · 2025 Callio Therapeutics Active Biotech US · 2025 Odyssey Therapeutics Active Biotech US · 2025 Aviceda Therapeutics Active
Metalloenzyme inhibitor compounds - Patent US-12370194-B2 - PubChem JavaScript is required... Please enable Javascript in order to use PubChem website.
Registration is... - Charcot-Marie-Tooth Association Facebook Log In Charcot-Marie-Tooth Association's Post Charcot-Marie-Tooth Association March 19 · Shared with Public Registration is officially open for the 2026 CMTA Patient & Research Summit in San Francisco Join CMTA from October 9-11 at the Grand Bay Hotel for a weekend full of connection, real conversations., and the latest in CMT research. Hear directly from leading experts, get updates on CMTA’s STAR initiatives, and learn what’s ahead for treatments and care. Whether you’re living with CMT, supporting someone who is, or just
Augustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier League Football Formula 1 Rugby Cricket Golf Tenni … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets close in 3h 36m UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets close in 3h 36m FTSE 100 10,440.46 -89.43 -0.85% GBP/USD 1.3214 +0.0017 +0.13% GBP/EUR 1.1590 -0.0007 -0.06% FTSE 250 22,934.19 -227.22 -0.98% AIM 765.77 -6.15 -0.80% GOLD FUTURES 4,061.90 +14 … Eli Lilly and Company, AdBio partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, the US-based Charcot-Marie-Tooth (CMT) Research Foundation and Newton Biocapital. For more information visit www.augustinetx.com Terms and Privacy Policy Privacy & Cookie Settings Recommended stories Copyright © 2026 Yahoo. All rights reserved. What's trending NVDA Tesla Apple MSFT Lloyds FTSE 100 Explore more Top Stocks Personal Finance Investing News Earnings Videos About Data disclaim
Augustine Therapeutics appoints Rie Schultz Hansen as CSO and establishes Copenhagen-based subsidiary | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Our portfolio companies keep delivering. Well done Team Augustine! | Christina Takke LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s U
DEF 14A Table of Contents DEF 14A false 0001827087 0001827087 2024-01-01 2024-12-31     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )     Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box:   ☐ Preliminary Proxy Statement   ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))   ☒ … ment, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply)   ☒ No fee required.   ☐ Fee paid previously with preliminary materials.   ☐ Fee computed on table in exhibit required by Item 25(b) per Securities Exchange Act of 1934 Rules 14a-6(i)(1) and 0-11.       Table of Contents VIGIL NEUROSCIENCE, INC. 100 Forge Road, Suite 700 Watertown, MA 02472 NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS To be h … reholdermeeting.com/VIGL2025, where you will be able to vote electronically and submit questions. You will need the 16-digit control number included with the Notice of Internet Availability of Proxy Materials being mailed to you separately in order to attend the Annual Meeting. Stockholders of record at the close of business on March 26, 2025, the record date for the Annual Meeting, are entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postp … 0;      Page   PROXY STATEMENT      1   PROPOSAL NO. 1 – ELECTION OF CLASS I DIRECTORS      7   PROPOSAL NO. 2 – RATIFICATION OF THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS VIGIL’S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025      12   CORPORATE GOVERNANCE      14   CERTAIN RELATIONSHIPS AND RELATED PARTY … th respect to those shares. As the stockholder of record, you have the right to grant your voting proxy directly to the individuals listed on the proxy card or vote on your own behalf at our virtual Annual Meeting. Throughout this proxy statement, we refer to these registered stockholders as “stockholders of record.” Street Name Stock
Sponsorship & Exhibit Options | ICNMD 2026 Skip to content ICNMD 2026 #ICNMD2026 SUBSCRIBE TO MAILING LIST Facebook-f X-twitter Linkedin About Message from the President About ICNMD ICNMD 2026 Committees Congress Secretariat Host Venue Related Events & Partners Past Congresses Future Congresses Contact Program CME Accreditation Program at a Glance Onsite Information Scientific Program Presenter Guidelines Call For Abstracts Patient’s Day Teaching Courses Joint Sessions Registration & Accommodation Registration Accommodation Social Events Sponsorship & Exhibits Sponsorship & … sponsorship to educational events involving drugs for human use are required to submit a pre-request for authorization to AIFA at least 70 days prior to the event. When is it not necessary? Please note that the AIFA authorization is *NOT* necessary when: A company promotes only medical devices or food supplements during a meeting (products without Marketing Authorization) but subjected to MEDTECH authorization (if the company is associated); When a company sponsors a meeting
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica … ized investors. Asabys Partners Search company , through its Sabadell Asabys II fund, has participated in a €78 million financing round for Augustine Therapeutics Search company , a biotechnology company developing novel therapies for neuromuscular, neurodegenerative, and cardiometabolic diseases. The oversubscribed Series A round was co-led by Jeito Capital Search company and Novo Holdings Search company , with participation from existing investors including Eli Lilly View c
Augustine Therapeutics (Group) - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with Versant Ventures to Launch Saturnus Bio Coulter Partners Places Vincent Metzler as CEO of Cellcolabs Europe Unveils a Record 35 … Graph Therapeutics Raises $5m Investment Led by Daphni Kos Technology Partners: Fund Reaches $123m with 3rd Closing Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events Metabolomics 2026 Buenos Aires BIO 2026 San Diego … ndon 2026 Advanced Therapies Europe 2026 Barcelona » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
Our team (featuring Rie Schultz Hansen, Virginie Cartage, Frederik Rombouts, Tugsan Tezil and Bianca Zweegman had the pleasure of attending the Private Capital Belgium 2025 Private Equity Awards… | Augustine Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choic
#augustinetx #appointment #newhire #hdac6 | Augustine Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Pr
Rie Schultz Hansen, PhD | Augustine Theraputics Skip to Main Content About Us Company Leadership Board of Directors Therapeutic Focus Pipeline Media Careers Back to team Back to team Back to team Back to team Back to team Back to team Back to team Back to team Rie Schultz Hansen, PhD Chief Scientific Officer Rie joined Augustine as CSO in May 2025. With more than 20 years’ experience in drug discovery and early-stage drug development, she is an experienced executive with a strong background in cardio-metabolic and inflammation-driven diseases as well as peptide therapeutics. Prior to joining A … ard member of the Peptide Therapeutics Foundation and a member of the DCAcademy Grant Committee (University of Copenhagen) and obtained her post doctorate in cardiovascular research. \ Get in Touch [email protected] [email protected] About Us Therapeutic Focus Pipeline Media Careers Site by Bunsen Privacy Policy © 2025 Augustine Therapeutics. All Rights Reserved.
A story of continued growth: the Augustine Tx journey LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy
Origin of Impact: Over 25 Years of VIB - Taking HDAC6 drugs from the lab to the clinic with Augustine Tx Skip to main content Origin of Impact: Over 25 Years of VIB Search Search Log in en English subscribe Log in Search Search en English subscribe Taking HDAC6 drugs from the lab to the clinic with Augustine Tx Taking HDAC6 drugs from the lab to the clinic with Augustine Tx The road that links basic research to the development and commercialization of life-changing therapies can be a long one. In the case of Charcot-Marie-Tooth disease (CMT), every single day counts. This debilitating illness
Augustine Therapeutics N.V. - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with Versant Ventures to Launch Saturnus Bio Coulter Partners Places Vincent Metzler as CEO of Cellcolabs Europe Unveils a Record 35 Ne … Graph Therapeutics Raises $5m Investment Led by Daphni Kos Technology Partners: Fund Reaches $123m with 3rd Closing Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events Metabolomics 2026 Buenos Aires BIO 2026 San Diego … ndon 2026 Advanced Therapies Europe 2026 Barcelona » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
#bioequity | Augustine Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Polic
Augustine Therapeutics appoints Gerhard Koenig as Chief Executive Officer as Company Prepares to Enter the Clinic | AdBio About us Team Portfolio News Contact Follow Follow Augustine Therapeutics appoints Gerhard Koenig as Chief Executive Officer as Company Prepares to Enter the Clinic Home 9 Uncategorized 9 Augustine Therapeutics appoints Gerhard Koenig as Chief Executive Officer as Company Prepares to Enter the Clinic Augustine Therapeutics appoints Gerhard Koenig as Chief Executive Officer as Company Prepares to Enter the Clinic by aline | Feb 13, 2025 | Uncategorized Search Searc … in Follow Us Follow Follow © 2025 AdBio partners by mlcom Legal Notice AFB Seed-Fund I is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing. Manage Consent
Gerhard Koenig, PhD | Augustine Theraputics Skip to Main Content About Us Company Leadership Board of Directors Therapeutic Focus Pipeline Media Careers Back to team Back to team Back to team Back to team Back to team Back to team Back to team Back to team Gerhard Koenig, PhD Chief Executive Officer Dr. Koenig took up his role as CEO of Augustine Therapeutics in January 2025 having served as a Non-Executive Director since May 2022, and as Executive Chairman since June 2024. Gerhard was CEO and Co-founder of Arkuda Therapeutics, a Boston-based biotech company focused on the development of lysos … nounced in January 2025. He is an advisor with Atlas Venture, a Boston-based VC fund, and is Board member on VIGIL Therapeutics. Prior to his current positions, Gerhard served as CEO of Quartet Medicine, CSO and Senior Vice President of FORUM Pharmaceuticals, Vice President of Scientific Programs and Evaluation at Fidelity Biosciences Group (now F' Prime Capital), and held multiple positions at pharmaceutical company Bayer. Gerhard received his PhD and MS degrees in mole
About Skip to Main Content About Us Company Leadership Board of Directors Therapeutic Focus Pipeline Media Careers \ About Us Redefining HDAC6 Therapeutics Founded in 2019 as a spin-off from VIB and KU Leuven, Augustine Therapeutics is pioneering a new era in HDAC6-targeted drug development. Our work builds on the groundbreaking research of Prof. Ludo Van Den Bosch, who uncovered HDAC6’s critical role in peripheral neuropathies like Charcot-Marie-Tooth (CMT) disease and Chemotherapy-Induced Peripheral Neuropathy (CIPN), as well as neurodegenerative disorders such as ALS. Ludo Van Den Bosch, Ph
#augustinetx #seriesa #cmt | Augustine Therapeutics | 15 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Pri
#womeninscience #stem #internationaldayofwomenandgirlsinscience #womeninstem #idwgs #girlsinscience | Augustine Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to jo
Delighted to join the Augustine Therapeutics team as Chair of the board. Impressive science, exciting potential for patients with unmet clinical needs, recognized by a recent raise with a €78M ($85M)… | Pascale Witz | 136 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update
Augustine Therapeutics - Asabys Partners Skip to main content Search Close Search Menu HOME PORTFOLIO TEAM NEWS CONTACT FOR INVESTORS Augustine Therapeutics Augustine Therapeutics is a Belgian biotech company founded in 2019 and a spin-off of VIB-KU Leuven. The company is developing a wide portfolio of best-in-class, novel, potent and subtype-selective small-molecule inhibitors of the enzyme HDAC6 (Histone DeACetylase 6) for the treatment of neurodegenerative and cardiometabolic diseases. The inhibition of HDAC6 plays a crucial role in axonal protection and regeneration by controlling internal
Clara Campàs, PhD - Asabys Partners Skip to main content Search Close Search Menu HOME PORTFOLIO TEAM NEWS CONTACT FOR INVESTORS Clara Campàs, PhD Co-founder and managing partner Managing partner and co-founder of Asabys. Clara currently serves on the board of directors of Ona Therapeutics, Nuage Therapeutics, ALLOX and Augustine Therapeutics. Formerly, Clara served as Strategy & Development Director at Kern Pharma and held several positions at Advancell, including being the managing director. Clara has served as a member of the Investment Committee of the venture capital firm HealthEquity
Clara Campàs, PhD | Augustine Theraputics Skip to Main Content About Us Company Leadership Board of Directors Therapeutic Focus Pipeline Media Careers Back to team Back to team Back to team Back to team Back to team Back to team Back to team Back to team Clara Campàs, PhD Managing Director and Co-Founder, Asabys Partners Clara Campàs-Moya is Managing Partner and co-founder of the venture capital firm Asabys Partners (Barcelona). As investor she is a board member at Ona Therapeutics, Sidekick Health, Nuage Therapeutics and ALLOX and formerly at Origo Biopharma (exited). Before founding Asabys,
Charcot-Marie-Tooth Disease - First Humans Dosed in New CMT Drug Trial L CMT WHAT IS CMT Charcot-Marie-Tooth disease (CMT) is one of the most common inherited nerve disorders. TYPES OF CMT Description of the most prevalent types of CMT. PATIENT RESOURCES Helpful patient care resources for the treatment & management of CMT. CMT UPDATES Read about CMT updates and the latest in CMT research. Access our archives since 2014. CMT CONNECT Webinars. Empower, Educate, Connect. CMT Research = TRIAD Therapeutic Research In Accelerated Discovery TRIAD = Academia + Government + Industry = GRIN … CMT community from NMD Pharma Dear members of the CMT... Allison Moore Receives Award for Community Impact in Research by Courtney | Jan 14, 2026 | Advocacy , Awareness , Featured , Gene Therapy , GRIN Patient Registry , Living with CMT , Research , Research and Critical Trials , TRIAD | 0 Comments Muscular Dystrophy Association’s Legacy Awards Honor Innovators in Clinical and Scientific... The Nerve to Cure Event, Columbia Missouri by Courtney | Aug 26, 2025 | GRIN Patient R … 1 of 7 1 2 3 4 5 ... » Last » Join the conversation Leave a Comment 0 Comments Submit a Comment Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Submit Comment Newsletter Join for notifications on events, campaigns, & news Success! First Name Last Name Email Subscribe Follow Follow Follow Follow Follow Follow Follow our CMT Sup
Mehdi Ainouche, PharmD | Augustine Theraputics Skip to Main Content About Us Company Leadership Board of Directors Therapeutic Focus Pipeline Media Careers Back to team Back to team Back to team Back to team Back to team Back to team Back to team Back to team Mehdi Ainouche, PharmD Partner, Jeito Capital Mehdi joined Jeito Capital, a global leading independent Private Equity fund, with €534 million under management based in Paris and New York in 2020, following the launch of the fund, and was involved in several investments and portfolio companies notably in the fields of neurology, ophthalmol
Augustine Therapeutics NV - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Augustine Therapeutics NV Startups | Holding Company | 2019 | Belgium | 10-50 | augustinetx.com Startups | Holding Company | 2019 | Belgium | 10-50 | augustinetx.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Nervous System Diseases Congenital Disorders Cardiovascular Diseases Small molecule drug Disease domain score A glimpse into the focused … Eli Lilly and Company, AdBio partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, the US-based Charcot-Marie-Tooth (CMT) Research Foundation and Newton Biocapital. For more information visit www.augustinetx.com Executive Change Acquisition 25 Mar 2025 · www.globenewswire.com Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investo … Eli Lilly and Company, AdBio partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, the US-based Charcot-Marie-Tooth (CMT) Research Foundation and Newton Biocapital. HDAC6 is involved in neurodegeneration and tissue aging-related cellular processes, and pharmacologic inhibition of HDAC6 is a promising approach in a number of diseases. Augustine Therapeutics have designed a unique next-generation approach to selectively inhibit HDAC6 while preserving its beneficial non-catal … and seed-funded by V-Bio Ventures, AdBio Partners, VIB, PMV, and Gemma Frisius Fund. The Company recently appointed experienced biopharma leader Gerhard Koenig, PhD, who had served as Executive Chairman since June 2024, to lead the Company as CEO in January 2025. The proceeds will be used to advance Augustine’s lead candidate, AGT-100216, through a Phase I/II proof-of-concept clinical trial in CMT. Beyond AGT-100216, Augustine has two other programs in discovery targeting pe … billion. www.novoholdings.dk. Jeito Capital is a global leading Private Equity fund with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significa
San Augustine TX Real Estate - San Augustine TX Homes For Sale | Zillow Skip main navigation Sign in Sign in Join Homepage Buy Open Buy sub-menu San Augustine homes for sale Homes for sale Foreclosures For sale by owner Open houses New construction Coming soon Recent home sales All homes Resources Home Buying Guide Foreclosure center Real estate app Down payment assistance Find a buyer's agent Rent Open Rent sub-menu San Augustine rentals Search apartments for rent Search houses for rent Search all rental listings Browse all rental buildings Tools for renters Estimate what you can afford … st For Sale by Owner Get a mortgage Open Get a mortgage sub-menu Started a loan application? Pick up where you left off on your Zillow Home Loans dashboard. Home loans dashboard Your mortgage Discover Zillow Home Loans Calculate your BuyAbility Get pre-qualified Mortgage tools Estimate your mortgage payment See current mortgage rates Learn about financing a home Find an agent Open Find an agent sub-menu Looking for pros? Real estate agents Home builders I'm a pro Agent s … Rental Manager Advertise Get help Sign in Sign in Join clear search text button Submit Search For Sale Price Beds & Baths Home Type Filters Save search San Augustine TX Real Estate & Homes For Sale 78 results Sort: Homes for You $55,500 2 bds 1 ba 1,275 sqft House for sale 1346 State Highway 21 E, San Augustine, TX 75972 More 7 days on Zillow Save $155,000 2 bds 1 ba 964 sqft House for sale 6524 State Highway 21, San Augustine, TX 75972 More Tile flooring Save Loading … 00 20 acres lot Lot / Land for sale 2824 Fm 705, Broaddus, TX 75929 More Gently rolling hills Save $145,474 28.95 acres lot Lot / Land for sale Fm 330, Milam, TX 75959 More Young pine plantation Save $445,000 89 acres lot Lot / Land for sale N County Road 143, San Augustine, TX 75972 More 87 days on Zillow Save Previous page Page 1 Page 2 Page 1 of 2 Next page Save this search to get email alerts when listings hit the market. For Sale Texas San Augustine County San Augustine
#raredisease #drugdevelopment #healthcareinnovation #research #charcotmarietooth #cmtrf #cmtresearch #cmtconvention | Augustine Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clickin
Emmanuelle Coutanceau, PhD | Augustine Theraputics Skip to Main Content About Us Company Leadership Board of Directors Therapeutic Focus Pipeline Media Careers Back to team Back to team Back to team Back to team Back to team Back to team Back to team Back to team Emmanuelle Coutanceau, PhD Partner, Novo Holdings She led several investment rounds and company creation efforts, and serves on the Boards of Corwave, Aloop, MinervaX, Draupnir, Heparegenix and BiOrigin.Emmanuelle has more than 15 years of experience in venture capital investment. Prior joining Novo Seeds, Emmanuelle was Partner Life … here she was in charge of seed stage investments for Auriga IV Bioseeds, a seed fund dedicated to projects related to infectiology and microbiology. From 2007 until 2014, she was part of Omnes capital (formerly Crédit Agricole Private Equity) life sciences team with multiple portfolio companies leading to successful exits or IPOs. She was also in charge of the Seed Stage Investment Program and actively invested and sat on the board of directors of several companies in Belgium
Augustine Therapeutics secures EUR 78M / USD 85M in Series A funding Products Data Feature Plans Request Demo Sign Up for Free Augustine Therapeutics secures EUR 78M / USD 85M in Series A funding 28 March 2025 Augustine Therapeutics NV , a biotech firm dedicated to creating innovative therapies for neuromuscular, neurodegenerative, and cardio-metabolic disorders, has successfully completed a Series A funding round, amassing EUR 77.7 million (USD 84.8 million). This financing phase was oversubscribed and co-led by Novo Holdings and Jeito Capital , with significant backing from existing inv … li Lilly and Company, AdBio Partners, V-Bio Ventures, PMV , VIB , Gemma Frisius Fund , the US-based Charcot-Marie-Tooth (CMT) Research Foundation, and Newton Biocapital. The funds raised will advance the clinical development of Augustine's lead compound, AGT-100216, intended for treating Charcot-Marie-Tooth (CMT) disease. CMT is the most prevalent hereditary disorder affecting the peripheral nervous system, impacting around three million people globally. Augustine plans to co … ormed and funded by V-Bio Ventures, AdBio Partners, VIB, PMV, and Gemma Frisius Fund. Recently, Gerhard Koenig, PhD, who has been with the company since June 2024 as Executive Chairman, was appointed CEO in January 2025. In addition to AGT-100216, Augustine is moving forward with two other discovery programs targeting HDAC6 inhibitors that are either peripheral-restricted or capable of crossing the blood-brain barrier, aimed at unspecified neurodegenerative and cardio-metabol
Augustine decloaks with $85m for nerve disease programme | pharmaphorum Skip to main content Friday 26 June 2026 BlueSky linkedin youtube header links Get Newsletters Media Kit Pharmaphorum menu first category News Views & Analysis Deep Dive Equity and Sustainability Research & Development Market Access Oncology Artificial Intelligence Patients & Partnerships GLP-1 Previous Editions Webinars Podcasts Videos Spotlight on ASCO BIO-Europe C-Suite Innovators ESMO Frontiers Health JP Morgan Global Policy Insights Events close SECTION News Views & Analysis Deep Dive Research & De … ys Partners, Eli Lilly, AdBio partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, the US-based Charcot-Marie-Tooth Research Foundation and Newton Biocapital. Image Phil Taylor 24 March, 2025 Charcot-Marie-Tooth Oncology CAR-T has a geography problem The gap between what CAR-T can do and who can actually get it is the defining challenge of this field right now. Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will
Augustine Theraputics Skip to Main Content About Us Company Leadership Board of Directors Therapeutic Focus Pipeline Media Careers September 3, 2024 Augustine Therapeutics Announces Appointment of Carl Bjartmar as Chief Medical Officer By Augustine Therapeutics Leuven, Belgium, September 03 2024 Augustine Therapeutics, a biotechnology company dedicated to advancing novel small molecule therapeutics for peripheral and neurodegenerative diseases, today announced the appointment of Carl Bjartmar, M.D., Ph.D., as Chief Medical Officer (CMO). Dr Carl Bjartmar is a skilled and experienced life scien … rtise will be immediately beneficial as we aim to file our first Clinical Trial Application with AGT100216, our lead program targeting Charcot-Marie-Tooth disease and other peripheral axonopathies.” Carl Bjartmar has a long and solid track record in clinical stage orphan drug clinical development at several biotech companies. At Wilson Therapeutics, he successfully led the late-stage development of Decuprate, a first-in-class treatment for Wilson’s rare genetic disease. He wa … orical investors AdBio partners, V-Bio Ventures, PMV, VIB and the Gemma Frisius Fund. For more information visit www.augustinetx.com \ Get in Touch [email protected] [email protected] About Us Therapeutic Focus Pipeline Media Careers Site by Bunsen Privacy Policy © 2025 Augustine Therapeutics. All Rights Reserved.
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
AGT-100216 - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 15 Nov 2025 AGT-100216 Last update 15 Nov 2025 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Small molecule drug Synonyms Selective HDAC6 inhibitors(Augustine Therapeutics), AGT 100216, AGT 216 + [1] Target HDAC6 Action inhibitors Mechanism HDAC6 inhibitors(Histone deacetylase 6 inhibitors), Epigenetic drug Therapeutic Areas Nervous System Diseases Congenital Disorders O … Eli Lilly and Company, AdBio partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, the US-based Charcot-Marie-Tooth (CMT) Research Foundation and Newton Biocapital. Charcot-Marie-Tooth (CMT) disease is a genetically heterogeneous group of hereditary peripheral neuropathies characterized by progressive distal nerve damage, primarily affecting the feet, legs, hands, and arms. The disorder damages peripheral nerves, causing muscle weakness, loss of sensation and other disabli … Eli Lilly and Company, AdBio partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, the US-based Charcot-Marie-Tooth (CMT) Research Foundation and Newton Biocapital. For more information visit www.augustinetx.com Executive Change Acquisition 01 Apr 2025 · medcitynews.com An AI Biotech Hauls In $600M, Plus More Funding Highlights to Close 1Q 2025 - MedCity News Isomorphic Labs, a young company whose artificial intelligence technology for drug research has already landed part … nerative, and cardio-metabolic diseases. The Leuven, Belgium-based company will apply the new capital to Phase 1/2 testing of lead program AGT-100216, an experimental treatment for rare neuromuscular disorder Charcot-Marie Tooth disease. Novo Holdings and Jeito Capital co-led Augustine’s Series A financing. —Osivax raised €10 million to continue development of OVX836, a broad-spectrum influenza vaccine candidate that has reached Phase 2b testing. The financing, which Lyon, Fr … gram to the preclinical research that could support an investigational new drug application (IND). San Francisco-based Montara develops “BrainOnly” drugs, therapies that selectively target the central nervous system while blocking harmful peripheral effects. With the expanded financing, the round now totals $28 million. —Ampersand Biomedicines re
Coulter Partners successfully places three senior executives at Augustine Therapeutics | Coulter Partners Coulter Partners About Solutions Sectors Insight Search website Menu About → Our approach Our team Join the team Diversity, Equity & Inclusion Geographic reach Candidates applications Contact us Solutions → Executive Search Board Advisory Leadership Consulting Sectors → Pharma / Biotech Medtech / Diagnostics Digital Health Agtech & Food production Industrial Biotech Animal Health Patients Services Enabling Services Investors Insight → News Events Close Search Search Close Global (E … diovascular research. She is also a member of the Danish Cardiovascular Academy Grant committee. Commenting on the appointments, Gerhard Koenig, PhD, CEO of Augustine , said: “Augustine is pioneering a new generation of HDAC6 inhibitors and has recently achieved a significant milestone by initiating its first clinical trial of lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth disease. To support the Company’s growth, we have significantly strengthened the man … Eli Lilly and Company, AdBio partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, the US-based Charcot-Marie-Tooth (CMT) Research Foundation and Newton Biocapital. For more information visit www.augustinetx.com About Coulter Partners We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that
Augustine Theraputics Skip to Main Content About Us Company Leadership Board of Directors Therapeutic Focus Pipeline Media Careers May 21, 2025 Augustine Therapeutics appoints Rie Schultz Hansen, PhD as Chief Scientific Officer and establishes Copenhagen-based subsidiary By Augustine Therapeutics New recruit expands senior team capabilities as the business progresses its lead HDAC6 inhibitor program, AGT-100216, into the clinic for the treatment of Charcot-Marie-Tooth Disease and continues building its pipeline in neurodegenerative and cardio-metabolic diseases Subsidiary Augustine Therapeutic … d has served for several years as a member of the Danish Cardiovascular Academy Grant committee. In addition, Augustine today announced the founding of a Copenhagen, Denmark based subsidiary, Augustine Therapeutics Denmark ApS, which will serve as the company’s hub for research related to cardio-metabolic diseases. Gerhard Koenig, PhD, CEO of Augustine Therapeutics commented: “Following the latest appointments of Virginie Cartage as Chief Financial Officer and Dr. Andy Hu as … ard member of the Peptide Therapeutics Foundation and a member of the DCAcademy Grant Committee (University of Copenhagen) and obtained her post doctorate in cardiovascular research. Media Contacts: Augustine Therapeutics Gerhard Koenig, CEO E-mail: [email protected] ICR Healthcare Amber Fennell E-mail: [email protected] About Augustine Therapeutics Augustine Therapeutics is a biotechnology company focused on the treatment of neuromuscular, neurodegenerative an … Eli Lilly and Company, AdBio partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, the US-based Charcot-Marie-Tooth (CMT) Research Foundation and Newton Biocapital. For more information visit www.augustinetx.com \ Get in Touch [email protected] [email protected] About Us Therapeutic Focus Pipeline Media Careers Site by Bunsen Privacy Policy © 2025 Augustine Therapeutics. All Rights Reserved.
Our History - Visit San Augustine Skip to content Visit San Augustine Things to Do 1919 County Jail Hardware on the Square Windows Into History Events Local Attractions Dining Shopping Hotels & Other Lodging Fishing & Water Sports Vineyards & Breweries About Our City Our History Parks & Outdoor Spaces Local Sports Contact X Get a Free Visitor's Guide City Chamber Main Street San Augustine History Texas Firsts Our History El Camino Real Visit Historical Sites Texas Firsts in San Augustine One of six earliest Spanish missions, the Mission Nuestra Senora de los Dolores de los Ais, … red then, as now, into a brilliance rivaling New England’s against gently rolling hills as green as Ireland’s. Driving further on El Camino Real, later called the Old San Antonio Road, Sam and Margaret would have passed the small burial ground dating from 1826, on a rise called Chapel Hill. Drive this way yourself and walk among the gravestones. As in other San Augustine cemeteries, very early settlers rest here. The stones name veterans of eight wars, including t
Augustine Therapeutics appoints Gerhard Koenig as Chief Executive Officer as Company Prepares to Enter the Clinic Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier League Football Formula 1 Rugby Cricket Golf T … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets close in 2h 54m UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets close in 2h 54m FTSE 100 10,427.00 -102.89 -0.98% GBP/USD 1.3205 +0.0008 +0.06% GBP/EUR 1.1578 -0.0019 -0.16% FTSE 250 22,900.28 -261.13 -1.13% AIM 765.61 -6.31 -0.82% GOLD FUTURES 4,060.50 +1
News & Events | City of San Augustine Texas Skip to main content NOTICE OF INTENT TO REQUEST RELEASE OF FUNDS NOTICE OF FINDING OF NO SIGNIFICANT IMPACT AND NOTICE OF INTENT TO REQUEST RELEASE OF FUNDS Contract GLO 24-065-071-E602 WWTP Improvement Winter Storm Fern Updates City of San Augustine Home Contact Us Visit San Augustine City of San Augustine Departments City Council Administration Fire Department Log Cabin Civic Center Main Street Municipal Court Police Department Public Library Public Works Sanitation Department by Piney Woods Senior Citizens Building Hotels - Where to Stay Resource … r spot in Texas history as well as the beautiful setting we enjoy, in the green rolling hills between two of the great lakes of Texas, Lake Sam Rayburn and Toledo Bend. Read more Police Department Jonathan Sowell - Chief LaTanja Greer - Administrative Assistant Weston Meier - Corporal Lydia Johnson - Detective/Patrol Officer Timothy Pruitt - Patrol Officer Tyler Johnson - Patrol Officer Jose Ocon - Patrol Officer Alexis Parnell - Patrol Officer Read more Public Works Water/Wa … d more Design & Technical Support This is placeholder text Read more Facade Grant Program This is placeholder text Read more Available Properties This is a placeholder Read more City of San Augustine CCR Reports (Water Quality Reports) Every year by July we will add another addition of documents giving overall information on the City's drinking water supply. Open the ducuments by clicking below on the year you want to view. Read more City Council Regular Meeting Read more … Council Regular Meeting Read more City Council Regular Meeting Read more Annual Fund Drive The San Augustine Volunteer Fire Department holds their Annual Fund Drive the month of July each year. Although this is the time period the majority of their donations are received, the SAVFD gladly appreciates donations received at any time. Donations can be mailed to: City of San Augustine Fire Department 301 South Harrison Street San Augustine, Texas 75972 Read more Donations Any pri … erce) - Aerial Photo by J Camp Ezekiel Cullen House - Photo by J Camp Read more RFP for Street Repairs for FEMA Project #34081 with the City of San Augustine RFP will be up on this site by 8am Friday, 8/10/2018. The Tribune only comes out on Thursday, so we had to place the ad in order to get this pricing started this week. Check back here tomorr
Congratulations!!!!! - City of San Augustine, TX Facebook Log In City of San Augustine, TX's Post City of San Augustine, TX October 3, 2025 · Shared with Public Congratulations!!!!! San Augustine Police Department October 2, 2025 · Shared with Public Congratulations, Officer Parnell The San Augustine Police Department proudly congratulates Officer Parnell on the successful completion of the Police Academy. This accomplishment is the result of dedication, discipline, and a commitment to public service. We look forward to the positive impact Officer Parnell will make in serving and protecti
Therapeutic Focus Skip to Main Content About Us Company Leadership Board of Directors Therapeutic Focus Pipeline Media Careers \ Therapeutic Focus The Right Target, The Right Chemistry, The Right Time HDAC6 isn’t like other HDACs. While most histone deacetylases act in the nucleus to regulate gene expression, HDAC6 is a unique, cytoplasmic enzyme that modulates a wide range of disease-relevant processes—including axonal transport, protein clearance, autophagy, oxidative stress, inflammation, and stress granule formation. In neurons, HDAC6 plays a pivotal role in maintaining axonal health by
Coulter Partners places executives at Augustine Therapeutics | Coulter Partners posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, … eek extended results, visual improvements in Stargardt & RP, and updates on rolling BLA submissions. 🔗 https://lnkd.in/eGRtQYxX PR Newswire 2️⃣ Regulatory, Platform & Strategy Moves ○ Kiora Pharmaceuticals to highlight pipeline at Eyecelerator & AAO – The company will present its retinal disease pipeline (KIO-301, KIO-104) and strategic plan to stakeholders at upcoming ophthalmology forums. 🔗 https://lnkd.in/eXgFkNB7 BioSpace 🚀 GreenScout delivers daily insight … not achieved remission with methotrexate or TNF inhibitors. The financing will fund a Phase 2 clinical trial (START-SYNERGY) in approximately 180 RA patients, expected to begin before the end of 2025, as well as exploratory work in other inflammatory and women’s health conditions. Vanessa Carle , PhD, Principal at Forbion, will join Elevara’s Board of Directors. This investment reflects Forbion’s continued focus on supporting transformational therapies that address high unme
Augustine Theraputics Skip to Main Content About Us Company Leadership Board of Directors Therapeutic Focus Pipeline Media Careers June 26, 2024 Augustine Therapeutics announces €17 million Series A1 financing round By Augustine Therapeutics AUGUSTINE THERAPEUTICS RAISES EUR 17 MILLION IN A SERIES A FIRST CLOSING TO ADVANCE LEAD CANDIDATE INTO CLINICAL DEVELOPMENT IN NEUROLOGICAL DISEASES Proceeds will advance lead candidate AGT100216, a peripherally restricted and selective HDAC6 inhibitor, into a first-in-human clinical Phase 1/2 study Gerhard Koenig appointed as executive chairman of August … Current investors AdBio partners , V-Bio Ventures , PMV , VIB and Gemma Frisius Fund also joined the round. Augustine Therapeutics is developing best-in-class, novel, potent and subtype-selective small-molecule inhibitors of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, a class II histone deacetylase. HDAC6 is a well-known molecular target with strong biological rationale for neurological disorders and high therapeutic potential in cardiometabolic disease. Inhibition of … trant properties for cardiometabolic and neurodegenerative diseases, as well as fund the expansion of the Augustine executive and R&D team. “The support from both new and existing investors in this first closing is a reflection of the tremendous efforts and scientific excellence of our team in advancing a unique pipeline of potential breakthrough therapeutics for patients” said Sylvain Celanire, CEO of Augustine Therapeutics . “Our HDAC6 inhibitors have unique properties
Augustine Therapeutics appoints Industry Veteran Pascale --> Accessibility: Skip TopNav Augustine Therapeutics appoints Industry Veteran Pascale Witz as Chair of its Board of Directors April 09, 2025 01:00 ET | Source: Augustine Therapeutics Augustine Therapeutics New Chair brings more than three decades of life sciences industry experience, with a successful track record as a biotech company board member Significant leadership experience will be instrumental as Augustine transitions into a clinical-stage company LEUVEN, Belgium – 9 April 2025 – Augustine Therapeutics NV (“Augustine” or … Eli Lilly and Company, AdBio partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, the US-based Charcot-Marie-Tooth (CMT) Research Foundation and Newton Biocapital. For more information visit www.augustinetx.com Tags Appointment HDAC6 Board New Hire GlobeNewswire Recommended Reading June 02, 2026 07:00 ET | Source: Augustine Therapeutics Augustine Therapeutics to Present Late-Breaking Poster at the American Diabetes Association’s 86th Scientific Sessions Poster will featur
San Augustine, TX (San Augustine County) Member Login Search Menu Home Handbook of Texas Education Shop Events Give Now About Us Join Today → BUY our latest TSHA Press book LA COLONIA MEXICANA DE MELVIN by ARNOLDO DE LEON today! Texas State Historical Association (TSHA) https://www.tshaonline.org San Augustine, TX (San Augustine County) https://www.tshaonline.org/handbook/entries/san-augustine-tx-san-augustine-county Home → Handbook of Texas → Entries → History and Development of San Augustine, Texas By: Vista K. McCroskey Published: 1952 Updated: February 12, 2019 Sa
Duc Tran, MSc | Augustine Theraputics Skip to Main Content About Us Company Leadership Board of Directors Therapeutic Focus Pipeline Media Careers Back to team Back to team Back to team Back to team Back to team Back to team Back to team Back to team Duc Tran, MSc Chief Development Officer Duc brings over 25 years of drug development experience spanning a broad range of therapeutic areas, including cardiovascular, anti-infective, urology, epigenetics, CNS, reproductive medicine, autoimmune diseases, and oncology. His experience covers the full drug development continuum, from lead optimization
Augustine Therapeutics–SEVERAL: investment, 202406 financing round Series A1 €17.5m led by Asabys Partners - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with Versant Ventures to Launch Saturnus Bio Coulter Par … Graph Therapeutics Raises $5m Investment Led by Daphni Kos Technology Partners: Fund Reaches $123m with 3rd Closing Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events Metabolomics 2026 Buenos Aires BIO 2026 San Diego … ndon 2026 Advanced Therapies Europe 2026 Barcelona » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
AGT-100216 - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 15 Nov 2025 AGT-100216 Last update 15 Nov 2025 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Small molecule drug Synonyms Selective HDAC6 inhibitors(Augustine Therapeutics), AGT 100216, AGT 216 + [1] Target HDAC6 Action inhibitors Mechanism HDAC6 inhibitors(Histone deacetylase 6 inhibitors), Epigenetic drug Therapeutic Areas Nervous System Diseases Congenital Disorders O … Eli Lilly and Company, AdBio partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, the US-based Charcot-Marie-Tooth (CMT) Research Foundation and Newton Biocapital. Charcot-Marie-Tooth (CMT) disease is a genetically heterogeneous group of hereditary peripheral neuropathies characterized by progressive distal nerve damage, primarily affecting the feet, legs, hands, and arms. The disorder damages peripheral nerves, causing muscle weakness, loss of sensation and other disabli … Eli Lilly and Company, AdBio partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, the US-based Charcot-Marie-Tooth (CMT) Research Foundation and Newton Biocapital. For more information visit www.augustinetx.com Executive Change Acquisition 01 Apr 2025 · medcitynews.com An AI Biotech Hauls In $600M, Plus More Funding Highlights to Close 1Q 2025 - MedCity News Isomorphic Labs, a young company whose artificial intelligence technology for drug research has already landed part … nerative, and cardio-metabolic diseases. The Leuven, Belgium-based company will apply the new capital to Phase 1/2 testing of lead program AGT-100216, an experimental treatment for rare neuromuscular disorder Charcot-Marie Tooth disease. Novo Holdings and Jeito Capital co-led Augustine’s Series A financing. —Osivax raised €10 million to continue development of OVX836, a broad-spectrum influenza vaccine candidate that has reached Phase 2b testing. The financing, which Lyon, Fr … gram to the preclinical research that could support an investigational new drug application (IND). San Francisco-based Montara develops “BrainOnly” drugs, therapies that selectively target the central nervous system while blocking harmful peripheral effects. With the expanded financing, the round now totals $28 million. —Ampersand Biomedicines re
Rent Silent Movie Screenings Headphones in San Augustine, TX Insights Support GET A QUOTE Nationwide Silent Disco ~ Rentals + Events + Products Call or Text: 800-674-3757 Rent Buy Services Headphone Rentals On-Site Activations Equipment Sales Custom Branding Experiences Dance Parties Health & Fitness Conferences Church & Worship About Meet the Team How It Works Locations Insights Support GET A QUOTE Get A Quote San Augustine Silent Movie Screenings ~ Texas Silent Film Screenings Headphone Rentals in San Augustine, TX Verified Reviews ❯ Turn any space into a private theater with silent headphon … outdoor venues, rooftops, parks, and community spaces where noise restrictions apply. With Silent Movie Screenings, every attendee enjoys immersive sound while the surrounding environment stays quiet and undisturbed across San Augustine County. Who rents silent headphones for movie screenings in San Augustine, TX? Movies are commonly rented by event planners, parks and recreation departments, schools, HOAs, and brands hosting outdoor movie nights in San Augustine, TX. They’r … ILENCE Activations, to opt-out reply STOP at any time. Msg & Data rates may apply. Terms – OR – Send us a text --> We're nationwide × Find your local city Search below to find service near you. Can't find your city? Browse by State →
Andy Hu - The Physician Who Builds Biotech Companies Breaking Andy Hu named Chief Business Officer of Augustine Therapeutics, April 2025 Joined permanently after serving as company advisor Former CBO of Arkuda Therapeutics, acquired by Johnson & Johnson Augustine closes oversubscribed $85M Series A Lead program AGT-100216 targets Charcot-Marie-Tooth disease An MD who reads balance sheets as fluently as biopsies Profile / Life Sciences Andy Hu A physician who chose the deal room over the exam room - and now steers the business of a biotech betting on a class of enzymes most people have neve
Andy Hu, MD | Augustine Theraputics Skip to Main Content About Us Company Leadership Board of Directors Therapeutic Focus Pipeline Media Careers Back to team Back to team Back to team Back to team Back to team Back to team Back to team Back to team Andy Hu, MD Chief Business Officer Andy brings diverse experience in corporate finance, strategy, and business development across the life sciences industry. Before joining Augustine, Dr. Hu was Chief Business Officer of Arkuda Therapeutics, a biotech company focused on neurodegenerative diseases which was acquired by Johnson & Johnson and annou
Physician – Infectious Disease (Inpatient & Outpatient) jobs near San Augustine, TX at HSHS. Physician – Infectious Disease (Inpatient & Outpatient) Company: Hospital Sisters Health System Location : San Augustine, TX, US Salary : $325,000-$340,000 per year Share : Apply for this job Apply for this job JobDetails Posted On: 06/16/2026 Valid Through: 07/14/2026 Employment Type: FULL TIME Job ID: 6a315482e376153722e1fa3b Postal Code: 75972 --> Description If you have additional questions, contact recruiter at: [email protected] you have additional questions, please contact the recruiter at: … iveness (PSLF) program Up to $150,000 in student loan assistance $2,500 monthly fellowship stipend upon signed contract Sign-on bonus Housing and relocation assistance Comprehensive benefits package, including generous vacation, retirement, and CME offerings Part of a clinically integrated healthcare delivery system with an established primary care referral base Position Details EPIC electronic medical record (EMR) system Dedicated clinical and administrative support staff H- … tious Disease M.D., D.O., or M.B.B.S. Compensation Pay range: $325,000–$340,000 Apply Today Submit your CV to [email protected] to begin your journey with HSHS Medical Group Core Function: Provider Education Qualifications Clinical doctorate is required. Experience Qualifications Competence in delivery of healthcare services for adolescents, adults and geriatric patients is required. Certifications, Licenses and Registrations Licensed physician in the state of practice i … ust have successfully completed, or in the process of completing, an accredited residency program. Must be board certified or board eligible. Job Description Throughout communities in Illinois and Wisconsin, 13 hospitals, numerous community-based health centers and clinics, our 13,000+ colleagues have built a culture based on our solid core values of respect, care, competence, and joy. These are the ideals we believe in, work by, and live each day. Built upon more than 145 ye … p to $7,500 for colleagues growing their families through adoption to reimburse application and legal fees, transportation, and more! • Other benefits include: Wellness program with incentives, employer-paid life insurance and short-term and long-term disability coverage, flexible spending accounts, employee assistance program, ID theft coverage,
#augustinetx #fundraise #milestone #biotech #charcotmarietooth #cmtafamily #cmtrf | Augustine Therapeutics | 41 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join o … m UnternehmerTUM Funding for Innovators, HTGF, and Boehringer Ingelheim Venture Fund. The company is advancing next-generation antibiotics targeting multi-drug resistant bacteria and has support from key figures such as Robert Macsics and Martin Falk. David Cendón Garcia | EU-Startups https://lnkd.in/e4BiyYpA #lifesciences smartbax secures €4.7 million as Germany confronts 10,000 deaths a year from drug-resistant infections | EU-Startups https://www.eu-startups.com Like Comme
ICNMD 2026 | Sponsorship & Exhibits Skip to content ICNMD 2026 #ICNMD2026 SUBSCRIBE TO MAILING LIST Facebook-f X-twitter Linkedin About Message from the President About ICNMD ICNMD 2026 Committees Congress Secretariat Host Venue Related Events & Partners Past Congresses Future Congresses Contact Program CME Accreditation Program at a Glance Onsite Information Scientific Program Presenter Guidelines Call For Abstracts Patient’s Day Teaching Courses Joint Sessions Registration & Accommodation Registration Accommodation Social Events Sponsorship & Exhibits Sponsorship & E … sponsorship to educational events involving drugs for human use are required to submit a pre-request for authorization to AIFA at least 70 days prior to the event. When is it not necessary? Please note that the AIFA authorization is *NOT* necessary when: A company promotes only medical devices or food supplements during a meeting (products without Marketing Authorization) but subjected to MEDTECH authorization (if the company is associated); When a company sponsors a meeting
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Augustine Theraputics Skip to Main Content About Us Company Leadership Board of Directors Therapeutic Focus Pipeline Media Careers April 9, 2025 Augustine Therapeutics appoints Industry Veteran Pascale Witz as Chair of its Board of Directors By Augustine Therapeutics New Chair brings more than three decades of life sciences industry experience, with a successful track record as a biotech company board member Significant leadership experience will be instrumental as Augustine transitions into a clinical-stage company LEUVEN, Belgium – 9 April 2025 – Augustine Therapeutics NV (“Augustine” or “th … Eli Lilly and Company, AdBio partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, the US-based Charcot-Marie-Tooth (CMT) Research Foundation and Newton Biocapital. For more information visit www.augustinetx.com \ Get in Touch [email protected] [email protected] About Us Therapeutic Focus Pipeline Media Careers Site by Bunsen Privacy Policy © 2025 Augustine Therapeutics. All Rights Reserved.
Augustine Theraputics Skip to Main Content About Us Company Leadership Board of Directors Therapeutic Focus Pipeline Media Careers September 10, 2024 Augustine Tx Sponsoring and Participating to the Annual Global CMT Research Convention on Sep 26-28 2024, Cambridge-MA By Augustine Therapeutics Augustine Therapeutics is proud to sponsor the 2024 Global CMT Research Convention, organized by the US CMT Research Foundation, to be held from September 26 th to 28 th 2024 at the Royal Sonesta Boston, Cambridge, MA. The event is gathering researchers, biotech and pharma companies, investors, and patie
Careers | Augustine Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy .
Careers | Augustine Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . … cal testing. For more information, please go to: https://lnkd.in/eEiMY5Hu ➡️ To apply, click here: https://lnkd.in/eccpH77E Careers augustinetx.com 101 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 5,872 followers View Profile Follow More from this author A story of continued growth: the Augustine Tx journey Augustine Therapeutics 4y Explore content categories Career Productivity Finance Soft Skills & Emotional Intelligence Projec